8-KEarnings & ResultsMaterial AgreementsExhibits & Filings

ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Agreement Terminated (Feb 7, 2013)

Filed February 7, 2013For Securities:ALNY

Summary

Alnylam Pharmaceuticals, Inc. (ALNY) reported a significant development regarding its ALN-RSV01 program on February 7, 2013. The company announced that Cubist Pharmaceuticals, Inc. has opted not to exercise its opt-in right for the ALN-RSV01 program, which targets respiratory syncytial virus infection in lung transplant patients. Consequently, Alnylam and Cubist have mutually agreed to terminate their License and Collaboration Agreement, effective February 6, 2013. This termination means that Alnylam retains full rights to the ALN-RSV01 program, without further obligations to Cubist under the terminated agreement. Investors should note that this event directly impacts the ALN-RSV01 program's future development and potential partnerships. The company also announced its financial results for the quarter and year ended December 31, 2012, with the full details available in the press release furnished with this 8-K filing.

Key Highlights

  • 1Cubist Pharmaceuticals, Inc. declined to opt-in to Alnylam's ALN-RSV01 program for respiratory syncytial virus (RSV) infection.
  • 2Alnylam Pharmaceuticals and Cubist Pharmaceuticals mutually agreed to terminate their License and Collaboration Agreement, effective February 6, 2013.
  • 3Alnylam retains all rights to the ALN-RSV01 program following the termination of the agreement.
  • 4The termination of the agreement will not result in further obligations or rights for either party regarding the ALN-RSV01 program.
  • 5The company also announced its financial results for the fourth quarter and full year ended December 31, 2012.
  • 6The press release containing the financial results is furnished as an exhibit to this Form 8-K.

Frequently Asked Questions

Cubist's decision not to opt-in means that Alnylam Pharmaceuticals retains full control and ownership of the ALN-RSV01 program. This allows Alnylam to independently pursue its development or seek other partnership opportunities for this specific program without further obligations to Cubist under the terminated agreement.

The mutual termination, effective February 6, 2013, signifies that both Alnylam and Cubist have no further rights or obligations to each other concerning the ALN-RSV01 program as per the original agreement and its amendments. It effectively concludes their collaboration on this specific asset.

The filing also includes the announcement of Alnylam's financial results for the quarter and year ended December 31, 2012. While the termination of the agreement is a key operational update, investors should refer to the furnished press release (Exhibit 99.1) for detailed financial performance and condition information.

No, the report explicitly states that as of the Effective Date of termination (February 6, 2013), the parties have no further rights and obligations under the Agreement. This implies a clean break regarding the ALN-RSV01 program under the terminated collaboration.